Several reports on aminoglycoside resistance have been published from different countries (1-3, 5, 11 -13, 15, 18, 21) . Resistance levels have varied greatly, depending on the nature of the hospitals studied and on the consumption of different aminoglycosides. Resistance mechanisms of aminoglycoside-resistant strains vary in different parts of the world (3, 19) . It is unclear which aminoglycoside-modifying enzymes are extant in Finland. The purpose of this study was to evaluate the present level of aminoglycoside resistance in blood culture isolates from the largest Finnish hospitals.
Before this study, several aminoglycosides were available for clinical use in Finland; gentamicin, tobramycin, and amikacin were the most frequently used in life-threatening infections. Netilmicin was approved for clinical use in the autumn of 1982.
(Part of this work was presented at the 13th International Congress of Chemotherapy, Vienna, Austria, August 1983.) MATERIALS AND METHODS Blood culture isolates from seven Finnish hospitals were collected during 1981 and 1982. All university central hospitals (in Helsinki, Tampere, Turku, Oulu, and Kuopio) were included. In addition, isolates from the Satakunta Central Hospital in Pori and from the Turku City Hospital were collected; they were collected from the former because of the emergence of some gentamicin-resistant gram-negative rods and from the latter because it represents a hospital with a majority of long-term patients. In addition, a few smaller hospitals from the county around the Oulu University Central Hospital and the Satakunta Central Hospital were included as a group. The natures of patients in the hospitals studied are quite similar, with the only exception being that of the Turku City Hospital as mentioned above. The number of beds and the mean duration of hospital stay for each hospital are described in Fig. 1 (17) . Ion concentrations were adjusted to 65 mg/liter for Ca2+ and 25 mg/liter for Mg2' by using an atomic absorption spectrophotometer (PerkinElmer 460; The Perkin-Elmer Corp., Norwalk, Conn). The inoculum size was controlled by using the most probable number method (6) . Control strains included in each assay were Escherichia coli K-12 and Staphylococcus aureus 209. During the study, MICs for the control strains were within the expected ranges. To determine the MICs, doubling concentrations were used; for gentamicin and tobramycin the range varied between 0.12 and 16 mg/liter, and for amikacin and netilmicin the range was between 0.25 and 32 mg/liter. Resistance breakpoints used were >4 mg/liter for gentamicin, tobramycin, and netilmicin and >8 mg/liter for amikacin (3) . Enzyme analysis of resistant strains was determined by the method described by Miller et al. (9) . Antimicrobial compounds required for enzyme or permeability detection (gentamicin, tobramycin, amikacin, netilmicin, sisomicin, 2'-netilmicin, 6'-netilmicin, pentisomicin, and Sch21420 [derivate of gentamicin B]) were kindly provided by G. Miller (Schering Corp., Bloomfield, N.J.).
The consumption of different aminoglycosides in 1981 in the hospitals studied is described in Fig. 2 . From 1979 to 1981 the consumption of gentamicin, tobramycin, and amikacin changed remarkably only in the Turku University Central Hospital; use of gentamicin decreased during the 3 years to 24% of that in 1979, the use of tobramycin and amikacin increased to 330 and to 290%, respectively, of that in 1979 (Fig. 3) . In all other hospitals, except the Turku City Hospital, gentamicin was the "drug of choice", and no clear changes in consumption occurred from 1979 Twelve other species were found with a frequency of less than 10 strains (Acinetobacter spp., Aeromonas hydrophila, Citrobacter freundii, Enterobacter spp., Morganella morganii, Proteus vulgaris, Providencia spp., Salmonella typhi, Salmonella brandenburg, Serratia marcescens, Staphylococcus hominis, and Yersinia enterocolitica).
Resistance to aminoglycosides was at a low level. Resistance to gentamicin occurred in 6.5%, tobramycin occurred in 5.1%, amikacin occurred in 1.3%, and netilmicin occurred in 3.8% of all isolates (n = 633) ( Table 2 ). The majority of the resistant strains were Staphylococcus epidermidis and Pseudomonas spp. (Tables 2 and 3 ). Of 115 strains of Staphylococcus epidermidis, 23 were gentamicin resistant (20%); tobramycin resistance occurred in 26 strains (23%). Staphylococci resistant to amikacin or netilmicin were not found. The frequency of resistant strains when Staphylococcus epidermidis and Pseudomonas sp. are excluded is also described in Table 2 . Escherichia coli was resistant only once to amikacin and once to tobramycin. One strain of Staphylococcus aureus showed resistance to tobramycin, and one showed resistance to gentamicin. Four strains of Pseudomonas spp. and two of Klebsiella spp. showed resistance to three or more aminoglycosides.
Contaminant staphylococci isolated from blood specimens in the Turku University Central Hospital and in the Satakunta Central Hospital were also tested; the numbers of such Staphylococcus epidermidis isolates were 39 in the Turku University Central Hospital and 17 in the Satakunta Central Hospital.
Enzyme-mediated resistance was found in 36 (55%) of 66 resistant bacteria studied (Table 4) Resistance enzymes of the contaminating Staphylococcus epidermidis isolated in the Turku University Central Hospital and in the Satakunta Central Hospital were also studied (Table 5 ). Among 17 strains collected from the Satakunta Central Hospital, only 1 was resistant to tobramycin with enzyme APH(2")-AAC(6'). In Turku, 33% of these staphylococci showed resistance against tobramycin. Of the 13 resistant strains studied, enzyme ANT(4') was found in 12 and enzyme APH(2")-AAC(6') was found in 1. Enzyme ANT(4') occurred thus in almost all resistant strains of contaminating Staphylococcus epidermidis (92%), but in only 6 of the 13 study, resistance among Enterobacteriaceae and Staphylococcus aureus was 1.0% or less (Table 2) . One should note that the high frequency of resistant Pseudomonas spp. (Table 2 ) observed may be due to the difficulty in determining aminoglycoside resistance in these bacteria (10, 14) . When the plate dilution method with unsupplemented Muller-Hinton agar (Oxoid Ltd.) was used, Pseudomonas strains resistant to tobramycin were found in 7.7%, to gentamicin and amikacin in 12%, and to netilmicin in 23%. When the disk diffusion test according to Ericsson et al. (4) was used, resistance varied from 3.8% for gentamicin and tobramycin to 7.7% for amikacin to 15.4% for netilmicin.
The most interesting enzyme modifying aminoglycoside resistance observed in this study is the adenylating enzyme ANT(4'), which has earlier been reported only in a few isolates. Miller et al. (9) found ANT(4') enzyme-mediated resistance in 17 of 1,306 aminoglycoside-resistant strains. Dornbusch et al. (3) reported five strains of staphylococci with ANT(4') enzyme. We observed 9 pathogenic and 12 other staphylococci with ANT(4') enzyme; 18 of these were isolated in the Turku University Central Hospital (Tables 4  and 5 ). The occurrence of this rare enzyme among the staphylococci in one particular hospital requires explanation. It seems most likely that changes in the aminoglycoside therapy policy in this hospital are responsible (Fig. 3) ; the extensive use of tobramycin and amikacin may have changed the normal hospital flora, encouraging strains with tobramycin resistance enzymes APH(2")-AAC(6) and ANT(4').
There are reports of gene transfer, even by conjugation between Staphylococcus aureus and Staphylococcus epidermidis (8) . It is thus possible that Staphylococcus aureus may have received the ANT(4') enzyme in this manner (Table 3 and 4).
The breakpoints used in this study are those described by Dornbusch et 
